Spark Biomedical announced on May 4 that it has appointed Anja Krammer as chief executive, with co-founder and outgoing CEO Daniel Powell transitioning to lead the company’s Neural Tourniquet hemorrhage-control programme through FDA approval and commercialisation. The leadership transition lands inside a fortnight that has produced four substantive milestones across bioelectronic-medicine companies operating at commercial inflection: Spark today, SetPoint Medical’s first multiple sclerosis pilot enrolment on April 30, ResMed’s $340 million acquisition of Noctrix Health on the same day, and Nervonik’s $52.5 million Series B on April 27. Read together, the cluster represents the cleanest fortnight-long signal yet that bioelectronic medicine is moving past early-clinical research and into the operational layer where commercial scaling, late-stage trials, incumbent acquisition, and growth-stage capital all start moving in parallel.

Each company sits at a different point in the same maturation arc.

Spark Biomedical

Spark, founded in Dallas, makes Sparrow Ascent, an FDA-cleared transcutaneous auricular neurostimulation device for opioid use disorder withdrawal — the first FDA-cleared noninvasive neurostim device for the indication. Spark has built a commercial relationship with electroCore for distribution. The CEO transition is the company’s tell: Krammer’s prior runs are scaling-stage cardiac, dermatology, and women’s-health medtech, which positions her to scale Sparrow’s commercial footprint while Powell focuses on the company’s pipeline product, the Neural Tourniquet, an experimental vagal/trigeminal stim device for hemorrhage control. The split formalises Spark as a multi-product bioelectronic platform rather than a single-indication startup.

SetPoint Medical

SetPoint announced on April 30 that it has begun enrolment in a multicenter, randomised, sham-controlled, double-blind pilot study evaluating its vagus nerve stimulation system as a pro-remyelination therapy for relapsing-remitting multiple sclerosis. The pilot runs adjunct to standard-of-care disease-modifying therapy. SetPoint already holds FDA Breakthrough Device Designation and acceptance into the FDA’s Total Product Life Cycle Advisory Programme, the same TAP designation CorTec joined two weeks ago for stroke motor rehabilitation. SetPoint is now the second BCI-adjacent company in the bioelectronic-medicine category to hold both Breakthrough and TAP, and the first to extend its vagus nerve platform from rheumatoid arthritis, its commercial-stage indication, into multiple sclerosis. The MS pilot is the first concrete data point on whether SetPoint’s neuroimmune-modulation thesis generalises beyond RA.

ResMed–Noctrix

On April 30, ResMed disclosed in its Q3 FY26 earnings transcript that it has agreed to acquire Noctrix Health for $340 million, with closing targeted for June 1. Noctrix’s flagship product, Nidra, is an FDA De Novo-classified noninvasive nerve stimulation device for refractory moderate-to-severe restless legs syndrome. Noctrix runs at approximately $24 million in current annual revenue with gross margin and growth rate higher than ResMed’s blended business; the acquisition is short-term EPS-dilutive (around $0.02 in Q4 FY26) and accretive on both ratios long-term. ResMed’s strategic logic is direct: it brings Noctrix’s wearable RLS therapy into the same HME and DME distribution channel ResMed leads in obstructive sleep apnea, with 10–30% comorbidity between RLS and OSA giving immediate cross-sell economics inside ResMed’s existing patient base. The deal is the largest commercial validation yet of peripheral nerve stimulation as a sleep-medicine product category, and the first time a sleep-medicine major has paid nine figures for a bioelectronic platform.

Nervonik

Nervonik closed an oversubscribed $52.5 million Series B on April 27, led by Amzak Health with Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital participating. The Los Angeles-based company is building a peripheral nerve stimulation platform with integrated stimulation and sensing capabilities, with early data demonstrating recording of evoked compound action potentials and other biomarkers using implantable leads. The closed-loop architecture (stim plus sense in the same implant) puts Nervonik in a different competitive position from open-loop peripheral nerve stim incumbents, with a positioning thesis built around real-time therapy personalisation rather than fixed dosing protocols.

The synthesis

The four data points map to four positions on a single arc: Nervonik (growth-stage capital for closed-loop architecture), SetPoint (late-stage trial entering a second indication), Spark (commercial-scaling CEO transition), ResMed–Noctrix (incumbent acquisition validating the sub-category). That sequence, capital to late-stage data to commercial scaling to incumbent acquisition, is the canonical maturation pattern for any medical-device category, and bioelectronic medicine has now produced examples of all four events inside a single fortnight.

For operators tracking the category, the practical read is that the bioelectronic-medicine acquisition window is open. ResMed paying $340 million for Noctrix establishes a pricing benchmark at roughly 14x current revenue for a single-indication peripheral nerve stim platform, which prices comparable platforms in the category accordingly. Companies further along, SetPoint with multi-indication validation, Spark with multi-product portfolio, Nervonik with closed-loop architecture, all become acquisition-relevant if their respective commercial milestones land. The incumbent universe of likely acquirers, which has historically meant Medtronic, Abbott, Boston Scientific, and Stryker for surgical-rehab adjacencies, has now been joined by sleep-medicine majors. That broadens the buyer pool meaningfully for the next round of deals.

The publishing question has shifted, from whether bioelectronic medicine clears the commercial-viability bar to which acquirers move first, at what multiples, and whether the Q1 2026 deal pace (ResMed–Noctrix following Synchron–Acquandas, Science Corp–Neurosoft, and Precision Neuroscience’s StealthStation integration with Medtronic) sustains through H2.